Status:

UNKNOWN

Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

Lead Sponsor:

Holterman, Ai-Xuan, M.D.

Collaborating Sponsors:

T Rose Clinical, Inc.

Big Leap Research

Conditions:

Biliary Atresia

Eligibility:

All Genders

14-180 years

Phase:

PHASE2

Brief Summary

The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of ...

Detailed Description

This is a prospective, randomized, multi-institutional trial in KBA and NoK subjects to be conducted under a Food and Drug Administration approved Investigational New Drug application. The KBA group ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • preliminary work up for cholestasis suspected or inconclusive diagnosis of BA.
  • Serum Direct bilirubin \> 2 mg/dl,GGT\> 100 U/L
  • Male or female infants with a gestational age\> 36 weeks
  • Admission weight \> 2 kg
  • Age \> 14 days - 180 days at diagnosis
  • For Kasai operated subjects, Type 3 or 4 anatomy of BA
  • For Kasai operated subjects, cholangiogram (if performed) diagnostic of BA
  • Liver biopsy supporting BA diagnosis
  • Exclusion criteria
  • Patients having access to liver transplantation for immediate liver failure
  • Prior Kasai patients
  • Major cardiac, renal, central nervous system (CNS) malformations
  • Intracranial hemorrhage
  • History of recent total parenteral nutrition (TPN) use within the last 2 weeks
  • Gl tract obstruction
  • For Kasai-operated subjects: Type 1 or 2 biliary atresia anatomy
  • Current systemic infection
  • WBC \> 20,000 cells/uL
  • Platelet count \< 20,000 cells/uL or \>1 million cells/uL
  • Concurrent respiratory, metabolic, neurological, cardiovascular, metabolic, and renal illness
  • Elevated serum creatinine \> 1 mg/dL
  • Purpura fulminans or unexplained vascular thrombosis

Exclusion

    Key Trial Info

    Start Date :

    September 1 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 31 2025

    Estimated Enrollment :

    400 Patients enrolled

    Trial Details

    Trial ID

    NCT04373941

    Start Date

    September 1 2023

    End Date

    October 31 2025

    Last Update

    September 8 2023

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Oregon Health & Science University (OHSU)

    Portland, Oregon, United States, 97239

    2

    Aga Khan University

    Karachi, Pakistan

    3

    Nation Children's Hospital

    Hanoi, Dong Da District, Vietnam

    4

    Children Hospital 1

    Ho Chi Minh City, Vietnam